Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,012 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
Lee J, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh DY, Shin DB, Kim TW, Lee N, Byun JH, Hong YS, Park JO, Park SH, Lim HY, Kang WK. Lee J, et al. Among authors: hong ys. Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63. doi: 10.1007/s00280-008-0913-5. Epub 2009 Jan 24. Cancer Chemother Pharmacol. 2009. PMID: 19169686 Clinical Trial.
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.
Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, Kim SY, Lee KW, Kim JH, Hong YS, Kim TW, Park YS, Kang WK, Shin SJ, Ahn JB, Kang GH, Jeong SY, Park KJ, Park JG, Kim TY. Lee KH, et al. Among authors: hong ys. Cancer Chemother Pharmacol. 2013 Apr;71(4):843-51. doi: 10.1007/s00280-013-2075-3. Epub 2013 Jan 13. Cancer Chemother Pharmacol. 2013. PMID: 23314736
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK. Lee J, et al. Among authors: hong jy, hong ys. Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Invest New Drugs. 2014. PMID: 24468885 Clinical Trial.
Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK. Lee J, et al. Among authors: hong jy, hong ys. Invest New Drugs. 2015 Feb;33(1):269-70. doi: 10.1007/s10637-014-0162-x. Invest New Drugs. 2015. PMID: 25236593 No abstract available.
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
Kim JE, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, Shin DB, Lee J, Park YS, Ahn JS, Kim TW. Kim JE, et al. Among authors: hong ys. Support Care Cancer. 2015 Jun;23(6):1769-77. doi: 10.1007/s00520-014-2507-6. Epub 2014 Dec 3. Support Care Cancer. 2015. PMID: 25465680 Clinical Trial.
Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study.
Kim JW, Lee YG, Hwang IG, Song HS, Koh SJ, Ko YH, Shin SH, Woo IS, Hong S, Kim TY, Kim SY, Nam BH, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Bae SH, Koo DH, Kim KI, Kim JH. Kim JW, et al. Among authors: hong s, hong ys. Br J Cancer. 2018 May;118(9):1169-1175. doi: 10.1038/s41416-018-0037-6. Epub 2018 Mar 26. Br J Cancer. 2018. PMID: 29576622 Free PMC article. Clinical Trial.
1,012 results